Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid

Eur Respir J. 2015 May;45(5):1498-501. doi: 10.1183/09031936.00176314. Epub 2015 Feb 19.

Abstract

MDR-TB patients treated with 6 months or more of delamanid had significantly lower likelihood of mortality http://ow.ly/HOv1d

Publication types

  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Biomarkers
  • Follow-Up Studies
  • Humans
  • Mycobacterium tuberculosis
  • Nitroimidazoles / therapeutic use*
  • Oxazoles / therapeutic use*
  • Prospective Studies
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Tuberculosis, Multidrug-Resistant / mortality*

Substances

  • Biomarkers
  • Nitroimidazoles
  • OPC-67683
  • Oxazoles